Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Claudia Stöllberger & Josef Finsterer. (2021) Update on drug interactions with non-vitamin-K-antagonist oral anticoagulants for stroke prevention in elderly patients. Expert Review of Clinical Pharmacology 14:5, pages 569-581.
Read now
Read now
Kristine C Willett & Amanda M Morrill. (2017) Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence. Therapeutics and Clinical Risk Management 13, pages 447-454.
Read now
Read now
Claudia Stöllberger. (2017) Drug interactions with new oral anticoagulants in elderly patients. Expert Review of Clinical Pharmacology 10:11, pages 1191-1202.
Read now
Read now
Erika Hellenbart, Beatrice Drambarean, James Lee & Edith A Nutescu. (2015) The evolving role of dabigatran etexilate in clinical practice. Expert Opinion on Pharmacotherapy 16:13, pages 2053-2072.
Read now
Read now
Articles from other publishers (29)
Elisabetta Palmerini, Francesco De Tommasi, Tamara Taddei, Stefano Amidei & Giovanni Falsini. (2022) Idarucizumab in Emergent Pericardiocentesis: A Case Report of Dabigatran-Induced Haemopericardium and Cardiac Tamponade. EMJ Cardiology.
Crossref
Crossref
Qingxia Zhang, Qian Ding, Suying Yan & Qun-Ying Yue. (2021) Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase. Frontiers in Pharmacology 12.
Crossref
Crossref
Jean-Paul Motta, Alexandre Denadai-Souza, David Sagnat, Laura Guiraud, Anissa Edir, Chrystelle Bonnart, Mireille Sebbag, Perrine Rousset, Ariane Lapeyre, Carine Seguy, Noa Mathurine-Thomas, Heather J. Galipeau, Delphine Bonnet, Laurent Alric, Andre G. Buret, John L. Wallace, Antoine Dufour, Elena F. Verdu, Morley D. Hollenberg, Eric Oswald, Matteo Serino, Celine Deraison & Nathalie Vergnolle. (2019) Active thrombin produced by the intestinal epithelium controls mucosal biofilms. Nature Communications 10:1.
Crossref
Crossref
G. Denise Zielinski, Martina Teichert, Frederikus A. Klok, Frits R. Rosendaal, Menno V. Huisman, Suzanne C. Cannegieter & Willem M. Lijfering. (2018) Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints. Pharmacoepidemiology and Drug Safety 27:12, pages 1371-1378.
Crossref
Crossref
Jung-Im Shin, Shengyuan Luo, G. Caleb Alexander, Lesley A. Inker, Josef Coresh, Alex R. Chang & Morgan E. Grams. (2018) Direct Oral Anticoagulants and Risk of Acute Kidney Injury in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 71:2, pages 251-252.
Crossref
Crossref
W.C.Y. Lau, X. Li, I.C.K. Wong, K.K.C. Man, G.Y.H. Lip, W.K. Leung, C.W. Siu & E.W. Chan. (2017) Bleeding‐related hospital admissions and 30‐day readmissions in patients with non‐valvular atrial fibrillation treated with dabigatran versus warfarin. Journal of Thrombosis and Haemostasis 15:10, pages 1923-1933.
Crossref
Crossref
Luigi Brunetti, Betty Sanchez-Catanese, Leonid Kagan, Xia Wen, Min Liu, Brian Buckley, James P. Luyendyk & Lauren M. Aleksunes. (2016) Evaluation of the chromogenic anti-factor IIa assay to assess dabigatran exposure in geriatric patients with atrial fibrillation in an outpatient setting. Thrombosis Journal 14:1.
Crossref
Crossref
Ying He, Ian C. K. Wong, Xue Li, Shweta Anand, Wai K. Leung, Chung Wah Siu & Esther W. Chan. (2016) The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. British Journal of Clinical Pharmacology 82:1, pages 285-300.
Crossref
Crossref
Claudia Stöllberger, Roman Brooks, Josef Finsterer & Thomas Pachofszky. (2016) Use of Direct-Acting Oral Anticoagulants in Nonagenarians: A Call for More Data. Drugs & Aging 33:5, pages 315-320.
Crossref
Crossref
Filiz KızılırmakHaci Murat GunesEkrem GulerGultekin Gunhan DemirOguz KaracaHabibe Gamze Canpolat. (2016) Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate. Korean Circulation Journal 46:1, pages 99.
Crossref
Crossref
Prasad S. Nishtala, Danijela Gnjidic, Hamish A. Jamieson, H. Carl Hanger, Chanaka Kaluarachchi & Sarah N. Hilmer. (2016) ‘Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. International Journal of Cardiology 203, pages 746-752.
Crossref
Crossref
Esther W. Chan, Wallis C.Y. Lau, Wai K. Leung, Michael T.C. Mok, Ying He, Teresa S.M. Tong & Ian C.K. Wong. (2015) Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study. Gastroenterology 149:3, pages 586-595.e3.
Crossref
Crossref
Laila Staerk, Gunnar H. Gislason, Gregory Y.H. Lip, Emil L. Fosbøl, Morten Lock Hansen, Morten Lamberts, Anders Nissen Bonde, Christian Torp-Pedersen & Jonas Bjerring Olesen. (2015) Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace 17:8, pages 1215-1222.
Crossref
Crossref
Julie Kalabalik, Gail B. Rattinger, Jesse Sullivan, Malgorzata Slugocki, Antonia Carbone & Anastasia Rivkin. (2015) Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. Drugs 75:9, pages 979-998.
Crossref
Crossref
Johannes W. Rey, Andreas Fischbach, Daniel Teubner, Marc Dieroff, Dominik Heuberger, Marc Nguyen-Tat, Hendrik Manner, Ralf Kiesslich & Arthur Hoffman. (2015) Acute gastrointestinal bleeding – a new approach to clinical and endoscopic management. European Journal of Gastroenterology & Hepatology 27:5, pages 483-491.
Crossref
Crossref
C. FENGER-ERIKSEN, A.-M. MÜNSTER & E. L. GROVE. (2014) New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. Acta Anaesthesiologica Scandinavica 58:6, pages 651-659.
Crossref
Crossref
Sascha Meyer dos Santos & Sebastian Harder. (2014) Benefit–Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation. Drug Safety 37:5, pages 295-307.
Crossref
Crossref
Ziv Harel, Michelle Sholzberg, Prakesh S. Shah, Katerina Pavenski, Shai Harel, Ron Wald, Chaim M. Bell & Jeffrey Perl. (2014) Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD. Journal of the American Society of Nephrology 25:3, pages 431-442.
Crossref
Crossref
A Carter, P Sarda, M George & S Corbett. (2014) Hip arthroplasty fatality related to dabigatran induced gastrointestinal haemorrhage. The Annals of The Royal College of Surgeons of England 96:1, pages e01-e03.
Crossref
Crossref
Claudia Stöllberger & Josef Finsterer. (2013) Concerns About the Use of New Oral Anticoagulants for Stroke Prevention in Elderly Patients with Atrial Fibrillation. Drugs & Aging 30:12, pages 949-958.
Crossref
Crossref
Anne M. Winkler & Christopher A. Tormey. (2013) Pathology Consultation on Monitoring Direct Thrombin Inhibitors and Overcoming Their Effects in Bleeding Patients. American Journal of Clinical Pathology 140:5, pages 610-622.
Crossref
Crossref
Jay Desai, Christopher B. Granger, Jeffrey I. Weitz & James Aisenberg. (2013) Novel oral anticoagulants in gastroenterology practice. Gastrointestinal Endoscopy 78:2, pages 227-239.
Crossref
Crossref
Diane Nitzki-George, Izabela Wozniak & Joseph A Caprini. (2013) Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors. Annals of Pharmacotherapy 47:6, pages 841-855.
Crossref
Crossref
Luigi Brunetti & Farooq Bandali. (2013) Dabigatran: Is There a Role for Coagulation Assays in Guiding Therapy?. Annals of Pharmacotherapy 47:6, pages 828-840.
Crossref
Crossref
Lisa M. Harinstein, Joseph W. Morgan & Nicholas Russo. (2012) Treatment of Dabigatran-Associated Bleeding. Journal of Pharmacy Practice 26:3, pages 264-269.
Crossref
Crossref
J. Desai, J. M. Kolb, J. I. Weitz & J. Aisenberg. (2013) Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies. Thrombosis and Haemostasis 110:2, pages 205-212.
Crossref
Crossref
Joseph K. Maddry, Mana Kouros Amir, Daniel Sessions & Kennon Heard. (2013) Fatal dabigatran toxicity secondary to acute renal failure. The American Journal of Emergency Medicine 31:2, pages 462.e1-462.e2.
Crossref
Crossref
Joonseok Kim, Mrinal Yadava, In Chul An, Abrar Sayeed, Heather S. Laird-Fick, Venu Gourineni & George S. Abela. (2013) Coagulopathy and Extremely Elevated PT/INR after Dabigatran Etexilate Use in a Patient with End-Stage Renal Disease. Case Reports in Medicine 2013, pages 1-4.
Crossref
Crossref
. (2013) Current World Literature. Current Opinion in Cardiology 28:1, pages 80-84.
Crossref
Crossref